CLAIMS

1. Use of 2-{3-[4-(1*H*-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-*N*-(propan-2-yl) acetamide or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of multiple myeloma.
2. The use of claim 1, wherein the 2-{3-[4-(1*H*-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-*N*-(propan-2-yl) acetamide or a pharmaceutically acceptable salt thereof, is to be administered as a monotherapy.
3. The use of claim 1, wherein the 2-{3-[4-(1*H*-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-*N*-(propan-2-yl) acetamide or a pharmaceutically acceptable salt thereof, is in combination with an anti-CD38 antibody.
4. The use of claim 3, wherein the anti-CD38 antibody is daratumumab, isatuximab, MOR202 or mezagitamab (TAK-079).
5. The use of claim 4, wherein the anti-CD38 antibody is isatuximab and wherein:
    a) the dose of isatuximab is of 10 mg/kg or 20 mg/kg to be administered intravenously;
    b) the dose of isatuximab is of 1000 mg or 1400 mg to be administered subcutaneously;
    c) the isatuximab is to be administered in a 28-day cycle;
    d) the isatuximab is to be administered in a 28-day cycle and in a first 28-day cycle, the isatuximab is to be administered once per week;
    e) the isatuximab is to be administered in a 28-day cycle and in a first 28-day cycle, the isatuximab is to be administered once per week and in subsequent 28-day cycles, the isatuximab is to be administered twice per week; or
    f) the isatuximab is to be administered in a 28-day cycle and in a first 28-day cycle, the isatuximab is to be administered once per week and in subsequent 28-day cycles, the isatuximab is to be administered twice per week, and after 12 months of isatuximab administration, the isatuximab is to be administered once every 4 weeks.
6. The use of claim 1, wherein the 2-{3-[4-(1*H*-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-*N*-(propan-2-yl) acetamide or a pharmaceutically acceptable salt thereof, is in combination with an immunomodulatory drug (IMiD).
7. The use of claim 6, wherein the IMiD is selected from pomalidomide, lenalidomide, thalidomide, iberdomide, and mezigdomide.

8. The use of claim 7, wherein the IMiD is pomalidomide and wherein:
    a) the dose of pomalidomide is of 4 mg once per day from day 1 to day 21 of a 28-day cycle; and/or
    b) the pomalidomide is to be administered orally.
9. The use of any one of claims 1-8, wherein the 2-{3-[4-(1*H*-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-*N*-(propan-2-yl) acetamide or a pharmaceutically acceptable salt thereof, is to be administered in a 28-day cycle.
10. The use of any one of claims 1-9, wherein the 2-{3-[4-(1*H*-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-*N*-(propan-2-yl) acetamide or a pharmaceutically acceptable salt thereof, is:
    a) at a dose equivalent to a dose of up to 1000 mg of the free base per day;
    b) at a dose equivalent to a dose of 200 mg of the free base once per day;
    c) at a dose equivalent to a dose of 200 mg of the free base twice per day;
    d) at a dose equivalent to a dose of 400 mg of the free base once per day; or
    e) at a dose equivalent to a dose selected from 500 mg of the free base per day, 600 mg of the free base per day, 700 mg of the free base per day, 800 mg of the free base per day, 900 mg of the free base per day, and 1000 mg of the free base per day.
11. The use of any one of claims 1-10, wherein the 2-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-N-(propan-2-yl) acetamide or a pharmaceutically acceptable salt thereof, is to be administered orally.
12. The use of any one of claims 1-11, wherein 2-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-N-(propan-2-yl) acetamide or a pharmaceutically acceptable salt thereof, is the mesylate salt of 2-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-N-(propan-2-yl) acetamide.
13. The use of any one of claims 1-12, in combination with concomitant corticosteroid therapy.
14. The use of claim 13, wherein the concomitant corticosteroid therapy is selected from dexamethasone, prednisone, and methylprednisolone.
15. The use of claim 1, in combination with:
    a) isatuximab and dexamethasone; or
    b) pomalidomide and dexamethasone.
16. The use of any one of claims 1-15, wherein the medicament is to be administered to a subject that has received prior therapy for treating the multiple myeloma.

17. The use of any one of claims 1-16, wherein the multiple myeloma is:
    a) relapsed multiple myeloma;
    b) relapsed and refractory multiple myeloma; or
    c) smoldering multiple myeloma.
18. The use of any one of claims 1-17, wherein the treatment overcomes IMiD resistance in a subject with multiple myeloma.